关键词: 肝癌, 新辅助治疗, 免疫治疗

Abstract: Some hot issues of neoadjuvant therapy for liver cancer             SONG Tian-qiang.  Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin’s Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin 300060, China
Abstract    Hepatocellular carcinoma（HCC）is a common liver malignancy leading to death worldwide. Surgical resection is a very important treatment option for HCC, but the high recurrence rate greatly limits the survival benefits of patients. Neoadjuvant therapy has become a routine treatment in a variety of solid tumors by controlling small metastatic lesions, reducing preoperative tumor load and reducing recurrence, but its effect on HCC has not been confirmed. In view of the rapid development of drugs for advanced HCC, perioperative treatment especially preoperative conversion therapy and neoadjuvant therapy, are being actively explored. Although neoadjuvant therapy is just in its infancy in the whole course of treatment of liver cancer, as a new strategy for the treatment of liver cancer, it will surely play an increasingly important role in the whole course of the treatment of liver cancer. However, it is very important to unify the population suitable for neoadjuvant therapy, the selection method, the criteria for evaluating the efficacy, and the research endpoints. Only studies based on the unified standard framework can provide high-level evidence.

Key words: hepatocellular carcinoma, neoadjuvant therapy, immunotherapy